BIGNOTTI, Eliana
 Distribuzione geografica
Continente #
NA - Nord America 3.623
EU - Europa 1.574
AS - Asia 1.448
SA - Sud America 230
AF - Africa 27
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 6.910
Nazione #
US - Stati Uniti d'America 3.549
CN - Cina 518
SG - Singapore 452
PL - Polonia 384
DE - Germania 231
IT - Italia 226
UA - Ucraina 209
BR - Brasile 207
HK - Hong Kong 167
FI - Finlandia 130
VN - Vietnam 102
GB - Regno Unito 92
TR - Turchia 52
CA - Canada 47
EE - Estonia 46
RU - Federazione Russa 46
IE - Irlanda 44
IN - India 37
FR - Francia 35
BD - Bangladesh 24
SE - Svezia 24
ES - Italia 22
ID - Indonesia 17
NL - Olanda 17
MX - Messico 16
BE - Belgio 14
CZ - Repubblica Ceca 14
ZA - Sudafrica 14
JP - Giappone 11
LT - Lituania 11
AR - Argentina 10
AT - Austria 10
IQ - Iraq 10
BG - Bulgaria 7
KG - Kirghizistan 6
KR - Corea 5
PK - Pakistan 5
AE - Emirati Arabi Uniti 4
EC - Ecuador 4
JO - Giordania 4
LK - Sri Lanka 4
SA - Arabia Saudita 4
TN - Tunisia 4
TW - Taiwan 4
AZ - Azerbaigian 3
CR - Costa Rica 3
EU - Europa 3
IL - Israele 3
PT - Portogallo 3
AU - Australia 2
BB - Barbados 2
CO - Colombia 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MA - Marocco 2
MU - Mauritius 2
MY - Malesia 2
OM - Oman 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
AQ - Antartide 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
CL - Cile 1
DZ - Algeria 1
EG - Egitto 1
ET - Etiopia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
IR - Iran 1
JM - Giamaica 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TJ - Tagikistan 1
TO - Tonga 1
VE - Venezuela 1
Totale 6.910
Città #
Fairfield 408
Warsaw 382
Ashburn 345
Woodbridge 297
Singapore 232
Houston 211
Seattle 201
Chandler 194
New York 158
Hong Kong 149
Jacksonville 147
Cambridge 136
Wilmington 132
Ann Arbor 121
Dearborn 109
Beijing 99
Helsinki 90
Los Angeles 85
Princeton 74
Munich 61
The Dalles 58
Brescia 50
Nanjing 47
Tallinn 46
Dublin 44
Istanbul 39
Shanghai 38
Des Moines 35
Dallas 32
Hangzhou 30
San Francisco 28
Chicago 26
Milan 26
Toronto 26
São Paulo 25
Buffalo 24
Dong Ket 24
Jinan 24
Ho Chi Minh City 23
Moscow 22
Hanoi 21
London 21
Nanchang 21
Shenyang 21
Kunming 19
Santa Clara 19
Turku 18
San Diego 15
Hebei 14
Tianjin 14
Brussels 13
Central 13
Redondo Beach 13
Rome 13
Changsha 12
Denver 12
Jakarta 12
Montreal 12
Brooklyn 11
Chennai 10
Guangzhou 10
Monmouth Junction 10
Phoenix 10
Tokyo 10
Belo Horizonte 9
Johannesburg 9
Poplar 9
Zhengzhou 9
Badalona 8
Boston 8
Jiaxing 8
Mexico City 8
Stockholm 8
Ankara 7
Atlanta 7
Brno 7
Charlotte 7
Hefei 7
Leawood 7
Ningbo 7
Nuremberg 7
Orem 7
Paris 7
Vienna 7
Amsterdam 6
Bishkek 6
Kilburn 6
Mumbai 6
Olomouc 6
Rio de Janeiro 6
Verona 6
Council Bluffs 5
Düsseldorf 5
Falkenstein 5
Manchester 5
Norwalk 5
Phủ Lý 5
Querétaro 5
Sofia 5
Taiyuan 5
Totale 4.882
Nome #
Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues 330
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Zhao S1, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD 319
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. 311
A prognostic regulatory pathway in stage I epithelial ovarian cancer: New hints for the poor prognosis assessment 214
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. 204
Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts 198
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone 194
Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer 189
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 188
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. 183
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes 180
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma 176
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. 176
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence 173
Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues. 172
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. 169
RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients 168
Gene expression profiling to improve prognostic characterization of olfactory neuroblastoma and to define new targetable pathways 166
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma 164
Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner. 164
Overexpression of mammaglobin B in epithelial ovarian carcinomas. 163
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis 163
Trefoil factor 3: a novel serum marker identified by gene expression profiling in highgrade endometrial carcinomas 154
Mammaglobin B expression in human endometrial cancer 154
Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: Implications for personalized cancer therapy 145
Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial 142
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome 138
Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma 130
Claudin-7 expression in human epithelial ovarian cancer 128
LncRNAs as novel indicators of patients' prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study 126
Claudin 7 downregulation is predictive of distant metastasis in high-grade serous carcinoma patients 126
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer 124
Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients 117
Gene expression profiling of olfactory neuroblastoma helps identify prognostic pathways and define potentially therapeutic targets 115
Improved Risk Prediction in Human Papillomavirus-Associated Endocervical Adenocarcinoma Through Assessment of Binary Silva Pattern-based Classification: An International Multicenter Retrospective Observational Study Led by the International Society of Gynecological Pathologists (ISGyP) 107
Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients 102
Integrated mutational landscape analysis of uterine leiomyosarcomas 97
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients 92
L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma 84
Uso di miRNA come biomarcatori per la diagnosi e prognosi del carcinoma orale a cellule squamose 83
Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes 78
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy 64
Correction for Li et al., Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors 63
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors 59
Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy 57
Identification of optimal reference RNAs to normalize miRNA expression data by qRT-PCR in formalin-fixed, paraffin-embedded lymph node tissue 55
The Oxford Classic can identify HGSOC patients who may benefit from EMT-targeting therapies 52
Circulating Serum Micro-RNA as Non-Invasive Diagnostic Biomarkers of Endometriosis 42
Development of a diagnostic model based on serum microRNAs for the diagnosis of endometriosis 20
Totale 7.018
Categoria #
all - tutte 30.722
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.722


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021537 0 0 0 0 0 78 44 81 75 141 68 50
2021/2022442 64 91 7 3 5 27 28 21 15 59 38 84
2022/2023493 76 32 25 32 47 102 8 52 69 6 24 20
2023/2024619 36 19 64 54 33 165 34 37 80 37 9 51
2024/20251.157 22 20 19 201 79 124 74 45 119 74 215 165
2025/20261.447 239 212 162 354 318 162 0 0 0 0 0 0
Totale 7.018